In addition, ACSL4 inhibition with rosiglitazone or specific siRNA can significantly suppress ferroptosis and further alleviate the progression of arsenic-induced NASH via restraining 5-HETE content [109]. This evidence concerns the gene ACSL4 and metabolic dysfunction-associated steatohepatitis.